Minolox 50mg Tablet 10s

Uses of Minolox 50mg Tablet 10s

Minocycline is used in certain bacterial infections such as pneumonia, acne and infections of the bladder, central nervous system, eye and prostate.

Side Effects of Minolox 50mg Tablet 10s

Oesophageal ulceration; vestibular disturbances e.g. dizziness or vertigo, tinnitus and decreased hearing; hyperpigmentation of the skin; SLE or lupus-like symptoms; GI disturbances; benign intracranial hypertension; abnormal LFTs, hyperbilirubinaemia or jaundice; teeth discolouration in children. Potentially Fatal: Hypersensitivity syndrome. Hepatitis or liver damage. Pneumonitis.

Drug Interactions

Oral absorption may be impaired by calcium-containing antacids and other divalent or trivalent cations. Decreases effectiveness of oral contraceptives. May increase plasma levels of lithium, theophylline. Pseudotumour cerebri may occur when used with isotretinoin. Additive facial pigmentation with ethinylestradiol. Potentially Fatal: May increase effects of oral anticoagulants.

Contraindications

Hypersensitivity to minocycline, other tetracyclines. Pregnancy and lactation.

Mechanism of Action

Minocycline inhibits protein synthesis by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. It is active against Streptococcus aureus, streptococci, Neisseria meningitidis, various enterobacteria, Acinetobacter, Bacteroides, Haemophilus and Nocardia spp, M. leprae and some mycobacteria. Absorption: Absorbed readily from the GI tract (oral); absorption not significantly affected by food and milk. Distribution: Protein-binding: 70-75%. Widely distributed in body tissues and fluids; high concentrations in hepatobiliary tract, lungs, sinuses, tonsils, tears, saliva, sputum. CSF (poor penetration). Crosses the placenta and enters breast milk. Metabolism: Some hepatic metabolism; converted to 9-hydroxyminocycline. Excretion: Via faeces (34%); via urine (5-10%). Elimination half-life: 11-26 hr; prolonged in renal impairment.

Special Precautions

May cause photosensitivity; discontinue at the 1st signs of erythema. May impair ability to drive or operate machinery. Monitor renal, hepatic and haematologic functions during therapy. Hepatic and renal impairment. Children ≤8 yr. Oral forms should be taken with plenty of fluids with the patient in an upright position.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.